Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BeyondSpring Inc.    BYSI   KYG108301006

BEYONDSPRING INC.

(BYSI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société BEYONDSPRING INC.
10/14Seed Therapeutics Launches Protein Degradation Research Platform and Appoints..
GL
10/12BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veter..
GL
09/29JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Ind..
GL
09/24New Data Highlights BeyondSpring's Plinabulin as a Highly Effective Agent for..
GL
09/22BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
GL
09/17BEYONDSPRING : Corporate Presentation
PU
09/11BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment ..
GL
09/08BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA an..
GL
09/03BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Upda..
GL
08/27BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Up..
GL
08/18BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology V..
GL
08/11BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients S..
GL
06/30New Stem Cell-Based Application for BeyondSpring's Plinabulin Presented at IS..
GL
06/25BEYONDSPRING : 2020 First Quarter Financial Report
PU
06/23New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Comb..
GL
06/19BeyondSpring Announces Pricing of Ordinary Shares
GL
06/18BeyondSpring Announces Proposed Public Offering of Ordinary Shares
GL
06/11BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Upd..
GL
06/09BeyondSpring's PROTECTIVE-2 (Study 106) Phase 2 Trial for Chemotherapy-Induce..
GL
06/03BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plin..
GL
06/02BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program
GL
05/13BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemother..
GL
04/30BEYONDSPRING : Study 106 Phase 2 Summary
PU
04/30BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and ..
GL
04/29CORRECTION – FDA Submission to Change the Primary Endpoint into an Indu..
GL
04/29FDA Submission to Change the Primary Endpoint into an Industry First and Robu..
GL
04/23BeyondSpring to Host Fourth-Quarter and Full-Year 2019 Financial Results and ..
GL
03/30BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin..
GL
03/23BeyondSpring's Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer P..
GL
03/17BEYONDSPRING : Market Opportunities & Strategies
PU
03/11BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Vira..
GL
03/09BEYONDSPRING : Corporate Presentation
PU
02/12BEYONDSPRING : Corporate Presentation
PU
02/10BeyondSpring's Plinabulin Stimulates Both the Adaptive and Innate Immune Syst..
GL
01/23BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanla..
GL
01/06BeyondSpring Strengthens Executive Rank for Pipeline Expansion and Commercial..
GL
2019BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Redu..
GL
2019BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Up..
GL
2019BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Upd..
GL
2019BeyondSpring's Study 106 Phase 3 Superior Trial Design Combining Plinabulin w..
GL
2019BeyondSpring's Abstracts on Clinical Evidence for Bone Marrow Stem Cell Prote..
GL
2019BEYONDSPRING'S SINGLE-BLINDED DESIGN : Data Accepted for Presentation at SITC 20..
GL
2019BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources
GL
2019BeyondSpring Announces Pricing of Ordinary Shares
GL
2019BeyondSpring Announces Proposed Public Offering of Ordinary Shares
GL
2019BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plin..
GL
2019Cell Journals Publishes BeyondSpring's New Data on Mechanism of Plinabulin to..
GL
2019BeyondSpring's Plinabulin Continues to Build on Superior Product Profile in B..
GL
2019BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Re..
GL
2019BeyondSpring's Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 201..
GL
2019BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment ..
GL
2019BeyondSpring's Plinabulin Demonstrates Superior Quality of Life Over Pegfilgr..
GL
2019BeyondSpring Announces Pricing of Public Offering of Ordinary Shares
GL
2019BeyondSpring Announces Proposed Public Offering of Ordinary Shares
GL
2019BeyondSpring Provides Operational Update and First Quarter 2019 Financial Res..
GL
2019BeyondSpring Set to Join FTSE Russell 3000® Index
GL
2019BeyondSpring to Present at the Jefferies 2019 Healthcare Conference
GL
2019BeyondSpring Files 2018 Annual Report on Form 20-F
GL
2019BeyondSpring to Host Fourth-Quarter and Full-Year 2018 Financial Results and ..
GL
2019BeyondSpring to Present at the 18th Annual Needham Healthcare Conference
GL
2019BeyondSpring's Lead Asset, Plinabulin, Shifts the Balance of Macrophages Towa..
GL
2019BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
GL
2019BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at 201..
GL
2019BeyondSpring Presents New Promising Data in Chemotherapy-Induced Neutropenia ..
GL
2018United States Patent and Trademark Office Issues Composition of Matter Patent..
GL
2018BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Che..
GL
2018Data for BeyondSpring's Lead Asset, Plinabulin, for Chemotherapy-Induced Neut..
GL
2018Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutr..
GL
2018Clinical Results for BeyondSpring's Lead Asset, Plinabulin for the Prevention..
GL
2018Beyondspring Provides Operational Update and Second-Quarter 2018 Financial Re..
GL
2018BeyondSpring to Host Second-Quarter 2018 Financial Results and Operational Up..
GL
2018Study Opens of BeyondSpring's Lead Asset, Plinabulin, and Nivolumab + Ipilimu..
GL
2018BeyondSpring to Present Clinical Trial Data at Three Upcoming Scientific Conf..
GL
2018BeyondSpring's Lead Asset, Plinabulin, Continues to Demonstrate Clinical Supe..
GL
2018BeyondSpring's Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Ne..
GL
1  2Next
Upcoming event on BEYONDSPRING INC.